Lilly sells Tippecanoe API site to Evonik

- Last updated on GMT

Related tags: Evonik

US drugmaker Eli Lilly will sell its Tippecanoe laboratories API manufacturing unit to Germany’s Evonik Industries.

The site in Lafayette, Indiana has been earmarked for sale since summer last year after Lilly unveiled plans to reduce capacity and buy in more drug ingredients and intermediates.

While financial terms of the deal are not being disclosed Lilly said that Evonik will use the facility to make certain active pharmaceutical ingredients for its human and animal health portfolios.

Lilly confirmed that the 700 members of staff at the site will be offered jobs by Evonik.

CEO John Lechleiter said that the sale supports "Lilly's goal to reduce our workforce and cost structure over time​,” adding that “we are taking the steps necessary to ensure our long-term success by becoming a leaner, more focused, more customer-oriented."

Related news

Related products

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...


NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Related suppliers

Follow us


View more